Compromised Microcirculation in Women With Polycystic Ovary Syndrome
NCT ID: NCT00757185
Last Updated: 2016-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
28 participants
INTERVENTIONAL
2008-02-29
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Exercise on Cardiometabolic Profile in Women With Polycystic Ovary Syndrome
NCT03678714
Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome
NCT01615562
PCOS, Therapy and Markers of Cardiovascular Risk
NCT01798875
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
NCT01462864
Health Risks and Barriers to Management Across the PCOS Lifespan
NCT05769426
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
GNRH antagonist alone
ganirelix acetate
GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
2
GnRH with Testosterone
methyl testosterone
testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ganirelix acetate
GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
methyl testosterone
testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nina Stachenfeld, PhD
Role: PRINCIPAL_INVESTIGATOR
John B. Pierce Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John B. Pierce Laboratory
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0801003437
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.